SunLink Health Systems, Inc. (NYSEMKT:SSY), net profit margin is 0.10% and weekly performance is 1.63%. On last trading day company shares ended up $1.25. Analysts mean target price for the company is $2.35. SunLink Health Systems, Inc. (NYSEMKT:SSY), distance from 50-day simple moving average (SMA50) is -8.93%.
Biostar Pharmaceuticals Inc (NASDAQ:BSPM) announced its financial results of the first quarter ended March 31, 2014. Revenue for the first quarter of 2014 increased 9.0% to approximately $13.2 million compared to $12.1 million for the first quarter of 2013. Net income was approximately $0.3 million for the first quarter of 2014, a decrease of approximately $0.3 million compared to the $0.6 million for the first quarter of 2013. Diluted earnings per share were $0.02 for the first quarter of 2014 compared to $0.06 for the first quarter of 2013, based upon approximately 13.0 million and 10.0 million diluted common shares outstanding, respectively. Biostar Pharmaceuticals Inc (NASDAQ:BSPM), advanced 5.26% in last trading session and ended the day on $1.40. BSPM, Gross Margin is 48.70% and its return on assets is 1.60%. Biostar Pharmaceuticals Inc (NASDAQ:BSPM), quarterly performance is -35.19%.
BMO Capital Markets boosted their price target on shares of Applied Genetic Technologies Corp (NASDAQ:AGTC), from $21.00 to $34.00 in a research note issued on Monday. The firm currently has an “outperform” rating on the stock. BMO Capital Markets’ target price points to a potential upside of 34.44% from the stock’s previous close. Applied Genetic Technologies Corp (NASDAQ:AGTC), shares moved up 6.26% in last trading session and was closed at $27.49, while trading in range of $23.30 – 29.63. Applied Genetic Technologies Corp (NASDAQ:AGTC), year to date (YTD) performance is 86.25%.
Agios Pharmaceuticals Inc (NASDAQ:AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism (IEMs), announced that its partner Celgene Corporation has exercised its option to an exclusive worldwide license to AG-221, an oral, first-in-class, potent inhibitor of the mutant IDH2 protein. Under the terms of the agreement, the option to license extended to Celgene through the end of Phase 1, but AG-221 has been exercised early based on the Phase 1 data generated to date. Agios Pharmaceuticals Inc (NASDAQ:AGIO), ended the last trading day at $47.50. Company weekly volatility is calculated as 5.80% and price to cash ratio as 9.95. Agios Pharmaceuticals Inc (NASDAQ:AGIO), showed a negative weekly performance of 11.01%.
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), announced the appointment of Melissa Bradford Klug as senior vice president of business development and strategy. Ms. Klug brings a wealth of hands-on business development, licensing and strategic partnering experience, as well as extensive leadership skills to AMAG’s executive team. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), net profit margin is -15.30% and weekly performance is 4.95%. On last trading day company shares ended up $19.31. Analysts mean target price for the company is $23.33. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), distance from 50-day simple moving average (SMA50) is 6.80%.
Leave a Reply